ArticleMycoses2019
Point-of-care diagnosis of invasive aspergillosis in non-neutropenic patients: Aspergillus Galactomannan Lateral Flow Assay versus Aspergillus-specific Lateral Flow Device test in bronchoalveolar lavage.
Article in Mycoses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Guideline
- Early Bedside Risk Stratification in ICU Patients with Suspected Invasive Pulmonary Aspergillosis: A Minimalist Clinical Decision Support Model.Journal of fungi (Basel, Switzerland) · 2026Article
- A machine learning-based risk prediction tool for early identification of invasive pulmonary aspergillosis in immunocompetent patients: a systematic review and meta-analysis.Journal of thoracic disease · 2026Article
- Integrative diagnosis of invasive pulmonary aspergillosis in non-neutropenic patients using BALF-tNGS-derivedFrontiers in cellular and infection microbiology · 2026Article
- Predictive nomogram for early detection of invasive fungal disease deterioration --- a 10-year retrospective cohort study.BMC infectious diseases · 2025Article
- Evaluation of a novel aspergillus IgG lateral flow assay for the diagnosis of non-neutropenic patients with acute and subacute invasive aspergillosis.Frontiers in cellular and infection microbiology · 2025Article
- Comparative Analysis of the Clarus Aspergillus Galactomannan Enzyme Immunoassay Prototype for the Diagnosis of Invasive Pulmonary Aspergillosis in Bronchoalveolar Lavage Fluid.Mycopathologia · 2024Article
- Performance of the Aspergillus galactomannan lateral flow assay with a digital reader for the diagnosis of invasive aspergillosis: a multicenter study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Drug-ResistantPathogens (Basel, Switzerland) · 2023Review
- Review
- The SSS revolution in fungal diagnostics: speed, simplicity and sensitivity.British medical bulletin · 2023Article
- Review
- Diagnosis and Treatment of Fungal Infections in Lung Transplant Recipients.Pathogens (Basel, Switzerland) · 2023Review
- Invasive Pulmonary Aspergillosis.Journal of fungi (Basel, Switzerland) · 2023Review
- COVID-19-Associated Pulmonary Aspergillosis (CAPA) in Northern Greece during 2020-2022: A Comparative Study According to the Main Consensus Criteria and Definitions.Journal of fungi (Basel, Switzerland) · 2023Article
- Article
- Monoclonal Antibodies and Invasive Aspergillosis: Diagnostic and Therapeutic Perspectives.International journal of molecular sciences · 2022Review
- Performance of the Euroimmun Aspergillus Antigen ELISA for the Diagnosis of Invasive Pulmonary Aspergillosis in Bronchoalveolar Lavage Fluid.Journal of clinical microbiology · 2022Article
- Aspergillus Lateral Flow Assay with Digital Reader for the Diagnosis of COVID-19-Associated Pulmonary Aspergillosis (CAPA): a Multicenter Study.Journal of clinical microbiology · 2022Article
- COVID-19-Associated Pulmonary Aspergillosis in a Tertiary Hospital.Journal of fungi (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundWe compared new Aspergillus Galactomannan Lateral Flow Assay with the newly formatted Aspergillus-specific Lateral Flow device tests for the diagnosis of invasive pulmonary aspergillosis (IPA) in non-neutropenic patients.
methodsWe performed both tests in 82 bronchoalveolar lavage fluid samples from 82 patients at risk for IPA but without underlying haematologic malignancy. Samples were collected between September 2016 and September 2018 at the University of California San Diego, United States. IPA was classified following two published consensus criteria.
resultsClassification of cases varied widely between the two consensus criteria. When using criteria established for the intensive care unit, 26/82 patients (32%) met criteria for proven or putative IPA. Both point-of-care assays showed sensitivities ranging between 58% and 69%, with specificities between 68% and 75%. Sensitivity increased up to 81% when both tests were combined.
conclusionThe study outlines the need for updated, unified and more broadly applicable consensus definitions for classifying IPA in non-neutropenic patients, a work that is currently in progress. Both point-of-care tests showed comparable performance, with sensitivities and specificities in the 60%-70% range when used alone and increasing to 80% when used in combination. The new point-of-care tests may serve a role at the bedside in those with clinical suspicion of IPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.